靶向CD20/CD3的b细胞淋巴瘤双特异性T细胞接合物:2023 EHA年会上的最新进展

IF 3.3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Chronic Disease Pub Date : 2023-12-04 eCollection Date: 2023-01-01 DOI:10.1177/20406223231215701

Shenhe Jin, Yi Liu, Ye Zhang, Fengping Zhou, Liangshun You, Jin Zhang

{"title":"靶向CD20/CD3的b细胞淋巴瘤双特异性T细胞接合物:2023 EHA年会上的最新进展","authors":"Shenhe Jin, Yi Liu, Ye Zhang, Fengping Zhou, Liangshun You, Jin Zhang","doi":"10.1177/20406223231215701","DOIUrl":null,"url":null,"abstract":"BiTE, has recently been approved in Europe for relapsed or refractory follicular lymphoma (R/R FL) treatment in adults who have received at least two prior systemic therapies. In a pivotal phase II study, 4 49 of 90 (54%) enrolled patients achieved CR at the end of treatment, with a 24-month PFS of 77%.","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231215701"},"PeriodicalIF":3.3000,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697048/pdf/","citationCount":"0","resultStr":"{\"title\":\"Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting.\",\"authors\":\"Shenhe Jin, Yi Liu, Ye Zhang, Fengping Zhou, Liangshun You, Jin Zhang\",\"doi\":\"10.1177/20406223231215701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BiTE, has recently been approved in Europe for relapsed or refractory follicular lymphoma (R/R FL) treatment in adults who have received at least two prior systemic therapies. In a pivotal phase II study, 4 49 of 90 (54%) enrolled patients achieved CR at the end of treatment, with a 24-month PFS of 77%.\",\"PeriodicalId\":22960,\"journal\":{\"name\":\"Therapeutic Advances in Chronic Disease\",\"volume\":\"14 \",\"pages\":\"20406223231215701\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697048/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Chronic Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20406223231215701\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223231215701","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting.

BiTE, has recently been approved in Europe for relapsed or refractory follicular lymphoma (R/R FL) treatment in adults who have received at least two prior systemic therapies. In a pivotal phase II study, 4 49 of 90 (54%) enrolled patients achieved CR at the end of treatment, with a 24-month PFS of 77%.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)

CiteScore

6.20

自引率

0.00%

发文量

108

审稿时长

12 weeks

期刊介绍： Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.